STARPHARMA HOLDINGS LIMITED

18.2%

13.0¢

Market Cap $54.36M

Healthcare Biotechnology

Starpharma Holdings Limited is an Australia-based biotechnology company. The principal... Starpharma Holdings Limited is an Australia-based biotechnology company. The principal activities of the Company consist of research, development and commercialization of dendrimer products for pharmaceutical and healthcare applications. Its portfolio of dendrimer-based products includes three clinical-stage DEP (dendrimer enhanced product) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products. It has developed a pipeline of novel DEP oncology products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, it has a preclinical pipeline of DEP radiopharmaceuticals and DEP Antibody-Drug Conjugates (ADCs) in development. Its VIRALEZE Nasal Spray is a broad-spectrum nasal spray intended to provide a protective barrier in the nose that traps and blocks cold/respiratory viruses. It also offers VivaGel BV and VivaGel Condom products. More

Latest Threads

Tag

Subject

SPL

A full blown bull run........??????

14:45

8.9K

14:45

Last post guessy

8.9K

SPL

Spoofing is illegal

03/09/25

592

03/09/25

Last post Teddyward

592

SPL

Telix versus Starpharma radiotheranostics

31/08/25

3.5K

31/08/25

Last post antibotter

3.5K

SPL

Big Week Ahead???

31/08/25

144

31/08/25

Last post thrasher

144

SPL

Ann: FY25 Key Financial Results and Annual Report

28/08/25

1.8K

28/08/25

Last post colin037

1.8K

SPL

Ann: $3.7M R&D Tax Incentive Received

28/08/25

135

28/08/25

Last post

ASX News

135

SPL

Novartis and Radiopharmaceuticles

26/08/25

170

26/08/25

Last post thrasher

170

SPL

Ann: 2025 Appendix 4G and Corporate Governance Statement

26/08/25

127

26/08/25

Last post

ASX News

127

See All Discussions

Timeline

$3.7M R&D Tax Incentive Received
28 Aug 09:30	Share

2025 Appendix 4G and Corporate Governance Statement
26 Aug 11:09	Share

FY25 Key Financial Results and Annual Report
26 Aug 10:55	Share

2025 Annual Report
26 Aug 10:47	Share

2025 Appendix 4E Preliminary Financial Report
26 Aug 10:42	Share

Quarterly Activities/Appendix 4C Cash Flow Report
31 Jul 09:49	Share

Notification of cessation of securities - SPL
08 Jul 08:53	Share

Change in substantial holding
04 Jun 08:19	Share

Change in substantial holding
03 Jun 16:28	Share

Quarterly Activities/Appendix 4C Cash Flow Report
30 Apr 09:33	Share

Notification of cessation of securities - SPL
04 Apr 10:05	Share

Application for quotation of securities - SPL
04 Apr 10:02	Share

Becoming a substantial holder
17 Mar 16:12	Share

Half Yearly Report and Accounts
26 Feb 09:44	Share

Quarterly Activities/Appendix 4C Cash Flow Report
29 Jan 10:16	Share

DEP Presentation at Targeted Radio Therapies Conference
16 Jan 14:58	Share

SPL receives positive FDA feedback on DEP SN38 for PROC
19 Dec 09:41	Share

Change of Director's Interest Notice - Ms Cheryl Maley
12 Dec 09:40	Share

Notification regarding unquoted securities - SPL
12 Dec 09:26	Share

DEP Presentation at Radiopharmaceuticals Summit
04 Dec 09:50	Share

Results of 2024 Reconvened Annual General Meeting
29 Nov 15:50	Share

AGM Notice of Reconvened Meeting
27 Nov 12:14	Share

Results of 2024 Annual General Meeting
26 Nov 17:15	Share

AGM Chair's address and CEO's presentation
26 Nov 13:23	Share

DEP SN38 Results Showcased at GI Cancer Conference
21 Nov 11:10	Share

Bell Potter Healthcare Conference Presentation
18 Nov 09:04	Share

Change of Director's Interest Notice
06 Nov 12:35	Share

Notification regarding unquoted securities - SPL
01 Nov 09:12	Share

Quarterly Activities/Appendix 4C Cash Flow Report
31 Oct 08:56	Share

Australian Microcap Conference Presentation
29 Oct 16:35	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 13.0¢		Change 0.020(18.2%)		Mkt cap ! $54.36M

Open	High	Low	Value	Volume
11.5¢	13.5¢	11.0¢	$25.52K	200.4K

Buyers (Bids)

No.	Vol.	Price($)
1	617923	13.0¢

Sellers (Offers)

Price($)	Vol.	No.
13.5¢	108845	7

View Market Depth

No.	Vol.	Price($)
1	617923	0.130
2	56308	0.125
1	50000	0.120
1	43350	0.115
3	13597	0.110

Price($)	Vol.	No.
0.135	102840	6
0.140	161341	4
0.145	112695	8
0.150	175000	3
0.155	50000	1

Last trade - 16.10pm 04/09/2025 (20 minute delay)


Last 13.5¢		Change 0.020 ( 20.0 %)
Open	High	Low	Volume
11.3¢	13.5¢	11.3¢	186899
Last updated 16.00pm 04/09/2025 ?

SPL (ASX) Chart

STARPHARMA HOLDINGS LIMITED

Latest Threads

Timeline

Featured News

Latest Articles

Starpharma (ASX:SPL) CEO announces resignation after 16 years

After 16 years of serving as Starpharma’s (ASX:SPL) CEO, Dr Jackie Fairley announced she intends to retire during 2024.

Starpharma (ASX:SPL) secures VIRALEZE regulatory approval in Malaysia

Starpharma (ASX:SPL) has secured regulatory approval for its VIRALEZE antiviral nasal spray in Malaysia.

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News